Efficacy of short duration sequential therapy versus standard intravenous therapy for patients with uncomplicated catheter related bacteremia due to S. aureus methicillin-susceptible. - FPS-COL-2013-06

FUNDACIÓN PÚBLICA ANDALUZA PROGRESO Y SALUD0 个研究点开始时间: 2013年3月6日最近更新: 2014年11月10日

适应症

试验速览

暂无简介。

•? Patients ? 18 years with a minimum weight of 40 kg.
•? Microbiological isolation of S. aureus susceptible to methicillin.
•? To start antibiotic treatment with drugs active against S. aureus within 72 hours from the onset of clinical manifestations.
•? Prescription of treatment must be prior, independent and decoupled patient inclusion in the study, corresponding exclusively to clinical practice.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 124
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 30

•? Polymicrobial bacteremia.
•? Neutropenic patients.
•? Patients addicted to intravenous drugs.
•? Patients with malignancies with expected survival less than 6 months.
•? Severe allergy to beta-lactams.
•? Creatinine clearance <20ml/min.
•? Need for hemodialysis, peritoneal dialysis or plasmapheresis.
•? Clinical signs of deep infection in the first five days of treatment (mucocutaneous lesions suggestive of IE, embolic events, suppurative thrombophlebitis.
•? Predictors of complicated bacteremia:
•Positive blood culture for 48-96 hours of starting treatment antistaphylococcal
•Clinical instability
•Signs of sepsis or persistent fever on day 4 of treatment
•Existence of joint prostheses or valvular or vascular, vascular catheter not removed within three days
•Underlying heart disease or endocarditis.
•? Patients who present at diagnosis concomitant infection by another organism.
•? Not have signed informed consent.

发起方

FUNDACIÓN PÚBLICA ANDALUZA PROGRESO Y SALUD